PDCD1 and colorectal cancer: In 2017, the first two immunotherapies (nivolumab and pembrolizumab) that target programmed cell death protein 1 (PD-1) were approved by the FDA for colorectal cancer with microsatellite instability-high or deficient mismatch repair solid tumors5.